ARS Pharmaceuticals, Inc. (SPRY) Misses Q3 EPS by 6c

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q3 EPS of ($0.52), $0.06 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $28.56 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• AI/ML Innovations plans $2M private placement on the CSE